Cytosorbents (NASDAQ:CTSO) Stock Passes Above 200-Day Moving Average – Here’s What Happened

Cytosorbents Co. (NASDAQ:CTSO)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.04 and traded as high as $1.31. Cytosorbents shares last traded at $1.31, with a volume of 179,236 shares changing hands.

Analyst Upgrades and Downgrades

CTSO has been the topic of a number of recent analyst reports. HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. StockNews.com assumed coverage on Cytosorbents in a report on Friday. They set a “hold” rating on the stock. Finally, D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Up 13.9 %

The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The stock’s fifty day simple moving average is $0.98 and its two-hundred day simple moving average is $1.04. The company has a market capitalization of $71.63 million, a price-to-earnings ratio of -3.64 and a beta of 0.61.

Institutional Trading of Cytosorbents

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its holdings in shares of Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents during the fourth quarter worth $99,000. Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Sargent Investment Group LLC lifted its holdings in shares of Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the last quarter. Finally, Skylands Capital LLC boosted its position in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares during the period. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.